2. Academic Validation
  3. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

  • Antimicrob Agents Chemother. 2008 May;52(5):1868-70. doi: 10.1128/AAC.01369-07.
Hiroshi Kakeya 1,  Yoshitsugu Miyazaki,  Hisato Senda,  Tsutomu Kobayashi,  Masafumi Seki,  Koichi Izumikawa,  Kazunori Yanagihara,  Yoshihiro Yamamoto,  Takayoshi Tashiro,  Shigeru Kohno
Affiliations

Affiliation

  • 1 Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. kakeya@nagasaki-u.ac.jp
PMID: 18299412 DOI: 10.1128/AAC.01369-07
Abstract

SPK-843, a new polyene Antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

Figures
Products